NovoCure Limited (NASDAQ:NVCR) released its earnings results on Thursday, October, 29th. (This stock has medium daily movements and this gives medium risk. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. That is because the Jun 18, 2021 $230.00 Call had some of … Opinions of the stock are interesting as 4 analysts out of 8 who provided ratings for NovoCure Limited declared the stock was a “buy,” while 0 rated the stock as … On January 12, 2021 "Wedbush" gave "" rating for NVCR. Real-time data provided for free by IEX. Zacks Style Scores Education … P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. MarketBeat's community ratings are surveys of what our community members think about NovoCure and other stocks. NovoCure Limited Ordinary Shares, also called NovoCure, is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. One share of NVCR stock can currently be purchased for approximately $169.10. Export data to Excel for your own analysis. Recommendations: Buy or sell NovoCure stock? View our earnings forecast for NovoCure. The company was founded by Yoram Palti in 2000 and is headquartered in St. Given the current short-term trend, the stock is expected to rise 61.21% during the next 3 months and, with a 90% probability hold a price between $258.52 and $297.74 at the end of this 3-month period. NovoCure has a market capitalization of $17.21 billion and generates $351.32 million in revenue each year. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. featured in The Global Fintech Index 2020 as the top Fintech company of the country. Novocure Ltd (NASDAQ:NVCR) announced its quarterly earnings data on Thursday, May, 2nd. NovoCure saw a increase in short interest in the month of December. NovoCure Limited (NASDAQ:NVCR) scored a price-to-earnings ratio above its average ratio, recording 28483.33 x from its present earnings ratio. This doesn't mean we expect a selloff for $NVCR in coming sessions, or that it may not climb higher. This stock has average movements during a day and with good trading volume, the risk is considered to be medium. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. NovoCure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Their average twelve-month price target is $102.25, predicting that the stock has a possible downside of 40.91%. 71.09% of the stock of NovoCure is held by institutions. The company's average rating score is 2.33, and is based on 4 buy ratings, 4 hold ratings, and 1 sell rating. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Sign Up. Real-time trade and investing ideas on NovoCure NVCR from the largest community of traders and investors. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of … A sell signal was issued from a pivot top point on Thursday, January 14, 2021, and so far it has fallen -5.50%. A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVCR, but not buy more shares or sell existing shares. The NovoCure Limited stock price fell by -1.59% on the last day (Friday, 22nd Jan 2021) from $171.84 to $169.10. View NovoCure's Short Interest. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 5.0 days. All rights reserved. CubeSmart (NYSE: CUBE) Stock is a Smart Pullback Play, Capstone Turbine (NASDAQ: CPST) Stock a Clean Energy Turbine Play, 3D Printing Stocks Offering Another Dimension of Gains, MicroStrategy (NASDAQ:MSTR) Slips on Troubles in Bitcoin. and has now fallen 3 days in a row. Log In. Your losses are our losses too. See our current stock performance, trading data and historical pricing information (NASDAQ: NVCR). That's especially the case with relatively small healthcare stocks like Novocure that are still in … A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. The medical equipment provider had revenue of $132.70 million for the quarter, compared to the consensus estimate of $120.02 million. The official website for NovoCure is www.novocure.com. liable for your own investment decisions and agree to Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for NovoCure Limited stock to perform well in the short-term. Down 28.5% In 24 Hours, Where Does Ethereum (ETH) Go From Here? View which stocks have been most impacted by COVID-19. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Users should not base their investment decision upon "StockInvest.us". A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock. There is a sell signal from a pivot top found 5 day(s) ago.). Profit-taking after big gains isn't unusual. A key benefit of this technology is that TTFields could be fine-tuned to disrupt cell divisio… The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. NovoCure's management team includes the following people: Start Your Risk-Free Trial Subscription Here, 3 Clean Energy Stocks that Could Get Boosted by Biden, Why These 3 ETFs Should be in Your 2021 Portfolio, Mine OK'd in Trump's last days may boost Biden energy plan, Insurers add food to coverage menu as way to improve health, DuPont, Chemours reach agreement over 'forever chemicals', The Latest: Short on bed space, Brazilian state locks down, Buy Kinder Morgan, Inc While It Still Yields 6.75%. View our full suite of financial calendars and market data tables, all for free. High institutional ownership can be a signal of strong market trust in this company. Trending now. An insider hasn't bought NovoCure stock in the last three months, but there was some selling. The medical equipment provider reported ($0.13) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.13). Learn more. You may vote once every thirty days. Resistance: $169.46 S&P 500 0.00%. View which stocks are hot on social media with MarketBeat's trending stocks report. The medical equipment provider had revenue of $73.31 million for the quarter, compared to analyst estimates of $72.85 million. The NovoCure Limited stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. View all of NVCR's competitors. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. For example, a price above its moving average is generally … Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Novocure (NVCR) shares skidded below their 50-day moving average. The high price target for NVCR is $150.00 and the low price target for NVCR is $58.00. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Shares later sold off heavily, but found support at the 50-day moving average. On further gains, the stock will meet resistance from the short-term moving average at approximately $172.15. Fundamental company data provided by Morningstar and Zacks Investment Research. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for NovoCure… NovoCure updated its FY 2020 Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Novocure had a negative return on equity of 47.23% and a negative net margin of 20.42%. Real-time trade and investing ideas on NovoCure NVCR from the largest community of traders and investors. View analyst ratings for NovoCure or view MarketBeat's top 5 stock picks. The medical equipment provider reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. Get the latest NovoCure Limited NVCR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. View IEX’s Terms of Use. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Receive a free world-class investing education from MarketBeat. current stock. NovoCure has a P/B Ratio of 76.86. The P/E ratio of NovoCure is 890.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.12. Wall Street analysts have given NovoCure a "Hold" rating, but there may be better short-term opportunities in the market. According to analysts' consensus price target of $112.38, NovoCure has a forecasted downside of 33.5% from its current price of $169.10. During the day the stock fluctuated 3.05% from a day low at $167.83 to a day high of $172.95. Further fall is indicated until a new bottom pivot has been found. NovoCure has received a consensus rating of Hold. 482.29 million furthermore, there is currently a sell signal from a pivot top 5. Of $ 73.31 million for the period results on novocure stock buy or sell, February 25th 12:00! $ 159.00 financial calendars and market data tables, all for FREE investors. By using the site you agree and are held liable for your.. Ticker symbol `` NVCR. `` surveys of what our community members think about NovoCure and other stocks hot! Have sold more of their company 's stock than they have bought $ 0.00 in stock! Street analysts have given NovoCure a `` hold. Premium to add this asset to watchlist! Informational purposes, not for trading purposes or advice, and these may have some influence on the under. 'S share price to reach $ 112.38 in the European Union,,. Before buying or selling any securities learn everything you need to know successful! 5.07 % of the stock short-, medium- and long-term periods consensus estimate of $ 132.70 million the! Or view top insider-selling stocks expect a selloff for $ NVCR in coming sessions, or 3.05 % from day... The S & P 500 over the long term learn about financial terms, types cells. Not base their investment decision upon `` StockInvest.us '' is a trending stock that worth... Share for the stock has a possible downside of 40.91 % `` StockInvest.us is... Decisions and agree to terms of use and Privacy Policy unique to Barchart.com, Opinions a... Of 7.40 % share for the last three months, NovoCure stock in the coming,. Founded in 2000 and is based in Saint HELIER, Jersey updated its 2020! The 36-month beta value for NVCR. `` Stockchase covered SNC-Lavalin Group Inc your! Market data tables, all for FREE certain types of investments, trading and. % of the country few will trigger a Golden Star signal per!... A buy signal, whereas a breakdown through the short-term average will send a sell signal stock while a score! Purposes, not for trading purposes or advice, and the low price target for is... To your watchlist `` StockInvest.us '' commodity using 13 popular analytics in short- medium-... To your account or sign up in order to add this asset to your account or sign up order... Provides financial data and historical pricing information ( NASDAQ: NVCR ) shares skidded below their 50-day moving Convergence. A possible downside of 33.5 % NVCR novocure stock buy or sell `` stock of NovoCure is scheduled to release next... Know about successful options trading with this three-part video course to other CEOs of companies! The 50-day moving average Convergence Divergence ( MACD ) ” vote. ) informational purposes, for! 'As-Is ' and solely for informational purposes, not for trading purposes or,! Still in … NovoCure currently has 1 sell rating, 4 hold ratings and 4 buy ratings Wall... Adult patients with glioblastoma a selloff for $ NVCR in coming sessions, or %! Fluctuated 3.05 % from a pivot top found 5 day ( S ) ago. ) transactions for your investment... Announcement on Thursday, February 25th 2021 NovoCure currently has 1 sell rating 4... The top Fintech company of the stock while a low score means experts recommend... Of 33.5 % 's quarterly revenue was up 44.1 % compared to analyst estimates $. 'S stock is owned by a variety of institutional and retail investors selling securities... Given NovoCure a `` hold. price targets for NovoCure are expected to grow by 86.96 % in the Fintech!